Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Lymphoid 1Dermatologic 1CNS 1Breast 1

Conditions

Waldenstrom Macroglobulinemia 1

Interventions

Rituximab 530Cyclophosphamide 425Vincristine 219Doxorubicin 192fludarabine phosphate 177Etoposide 167Prednisone 166fludarabine 162Methotrexate 162Cytarabine 157Filgrastim 125Dexamethasone 123Lenalidomide 121Granulocyte Colony-Stimulating Factor 116Whole-Body Irradiation 107Mycophenolic Acid 99ibrutinib 97Bendamustine Hydrochloride 91Tacrolimus 88Melphalan 85Calcium Dobesilate 82Peripheral Blood Stem Cell Transplantation 80Bortezomib 80Busulfan 78obinutuzumab 64ofatumumab 59Radiotherapy 57Cyclosporine 57Antilymphocyte Serum 55Brentuximab Vedotin 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Valacyclovir × Lymphoid × Clear all
NCT00492050 2026-03-11

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
46 enrolled 10 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡